Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| IDH1 / IDH2 <10% in primary glioblastoma | 70-80% | IDH1/2 mutation in grade 2-3 glioma | cBioPortal (TCGA) |
| EGFR EGFRvIII in ~25-30% | 40-50% | Amplification | cBioPortal (TCGA) |
| PRMT5 (MTAP-deleted cancers) | 40% | MTAP deletion | |
| PDGFRA | 15% | amplification |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
6 cell lines, 1 mouse models and 5 repositories are listed for this cancer. See them →